Literature DB >> 31720876

Angiotropism, pericytic mimicry and extravascular migratory metastasis: an embryogenesis-derived program of tumor spread.

Claire Lugassy1, Hynda K Kleinman2, Peter B Vermeulen3,4, Raymond L Barnhill5,6.   

Abstract

Intravascular dissemination of tumor cells is the accepted mechanism of cancer metastasis. However, the phenomenon of angiotropism, pericyte mimicry (PM), and extravascular migratory metastasis (EVMM) has questioned the concept that tumor cells metastasize exclusively via circulation within vascular channels. This new paradigm of cancer spread and metastasis suggests that metastatic cells employ embryonic mechanisms for attachment to the abluminal surfaces of blood vessels (angiotropism) and spread via continuous migration, competing with and replacing pericytes, i.e., pericyte mimicry (PM). This is an entirely extravascular phenomenon (i.e., extravascular migratory metastasis or EVMM) without entry (intravasation) into vascular channels. PM and EVMM have mainly been studied in melanoma but also occur in other cancer types. PM and EVMM appear to be a reversion to an embryogenesis-derived program. There are many analogies between embryogenesis and cancer progression, including the important role of laminins, epithelial-mesenchymal transition, and the re-activation of embryonic signals by cancer cells. Furthermore, there is no circulation of blood during the first trimester of embryogenesis, despite the fact that there is extensive migration of cells to distant sites and formation of organs and tissues during this period. Embryonic migration therefore is a continuous extravascular migration as are PM and EVMM, supporting the concept that these embryonic migratory events appear to recur abnormally during the metastatic process. Finally, the perivascular location of tumor cells intrinsically links PM to vascular co-option. Taken together, these two new paradigms may greatly influence the development of new effective therapeutics for metastasis. In particular, targeting embryonic factors linked to migration that are detected during cancer metastasis may be particularly relevant to PM/EVMM.

Entities:  

Keywords:  Angiotropism; Embryonic-like migration; Extravascular migratory metastasis (EVMM); Laminins; Melanoma; Neural crest; Pericytic mimicry (PM); Vascular Co-option

Mesh:

Year:  2019        PMID: 31720876     DOI: 10.1007/s10456-019-09695-9

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   9.596


  18 in total

1.  Exploration of Pericyte-Derived Factors Implicated in Lung Cancer Brain Metastasis Protection: A Pilot Messenger RNA Sequencing Using the Blood-Brain Barrier In Vitro Model.

Authors:  Kenta Ujifuku; Takashi Fujimoto; Kei Sato; Yoichi Morofuji; Hideki Muto; Hiroshi Masumoto; Shinsuke Nakagawa; Masami Niwa; Takayuki Matsuo
Journal:  Cell Mol Neurobiol       Date:  2020-11-02       Impact factor: 5.046

2.  Perivascular infiltration reflects subclinical lymph node metastasis in invasive lobular carcinoma.

Authors:  Akiko Igawa; Hiroki Mizukami; Kazuhiro Kudoh; Yuki Takeuchi; Takanori Sasaki; Xuekai Pan; Kenichi Hakamada
Journal:  Virchows Arch       Date:  2022-08-10       Impact factor: 4.535

Review 3.  Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.

Authors:  Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix
Journal:  Br J Cancer       Date:  2022-06-01       Impact factor: 9.075

Review 4.  Vessel co-option and angiotropic extravascular migratory metastasis: a continuum of tumour growth and spread?

Authors:  Claire Lugassy; Peter B Vermeulen; Domenico Ribatti; Francesco Pezzella; Raymond L Barnhill
Journal:  Br J Cancer       Date:  2022-01-05       Impact factor: 9.075

Review 5.  Targeting metastatic cancer.

Authors:  Karuna Ganesh; Joan Massagué
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

Review 6.  Rethinking the biology of metastatic melanoma: a holistic approach.

Authors:  Hendrik Hld Vandyck; Lisa M Hillen; Francesca M Bosisio; Joost van den Oord; Axel Zur Hausen; Véronique Winnepenninckx
Journal:  Cancer Metastasis Rev       Date:  2021-04-19       Impact factor: 9.264

Review 7.  Metastasis-Initiating Cells and Ecosystems.

Authors:  Joan Massagué; Karuna Ganesh
Journal:  Cancer Discov       Date:  2021-04       Impact factor: 38.272

8.  Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value.

Authors:  Raymond Barnhill; Pieter-Jan van Dam; Peter Vermeulen; Gabriel Champenois; André Nicolas; Robert V Rawson; James S Wilmott; John F Thompson; Georgina V Long; Nathalie Cassoux; Sergio Roman-Roman; Klaus J Busam; Richard A Scolyer; Alexander J Lazar; Claire Lugassy
Journal:  J Pathol Clin Res       Date:  2020-04-18

Review 9.  Molecular Perspectives of Mitophagy in Myocardial Stress: Pathophysiology and Therapeutic Targets.

Authors:  Haizhe Ji; Dan Wu; O'Maley Kimberlee; Ruibing Li; Geng Qian
Journal:  Front Physiol       Date:  2021-06-30       Impact factor: 4.755

Review 10.  Roles for growth factors and mutations in metastatic dissemination.

Authors:  Nishanth Belugali Nataraj; Ilaria Marrocco; Yosef Yarden
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.